These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 24060523)

  • 21. Olmesartan/amlodipine: blood pressure lowering and beyond in special populations.
    Erdine S
    Ther Adv Cardiovasc Dis; 2012 Feb; 6(1):31-44. PubMed ID: 22222315
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination therapy with irbesartan and efonidipine for attenuation of proteinuria in Dahl salt-sensitive rats.
    Takai S; Jin D; Sakonjo H; Miyazaki M
    Hypertens Res; 2010 Sep; 33(9):953-9. PubMed ID: 20520612
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prospective direct comparison of antihypertensive effect and safety between high-dose amlodipine or indapamide in hypertensive patients uncontrolled by standard doses of angiotensin receptor blockers and amlodipine.
    Okamura K; Shirai K; Totake N; Okuda T; Urata H
    Clin Exp Hypertens; 2018; 40(2):99-106. PubMed ID: 28692311
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative Effects of an Angiotensin II Receptor Blocker (ARB)/Diuretic vs. ARB/Calcium-Channel Blocker Combination on Uncontrolled Nocturnal Hypertension Evaluated by Information and Communication Technology-Based Nocturnal Home Blood Pressure Monitoring　- The NOCTURNE Study.
    Kario K; Tomitani N; Kanegae H; Ishii H; Uchiyama K; Yamagiwa K; Shiraiwa T; Katsuya T; Yoshida T; Kanda K; Hasegawa S; Hoshide S
    Circ J; 2017 Jun; 81(7):948-957. PubMed ID: 28321001
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Irbesartan, an angiotensin receptor blocker, exhibits metabolic, anti-inflammatory and antioxidative effects in patients with high-risk hypertension.
    Taguchi I; Toyoda S; Takano K; Arikawa T; Kikuchi M; Ogawa M; Abe S; Node K; Inoue T
    Hypertens Res; 2013 Jul; 36(7):608-13. PubMed ID: 23425956
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of the effects of quinapril and irbesartan on P-wave dispersion in hypertensive patients.
    Guntekin U; Gunes Y; Tuncer M; Simsek H; Gunes A
    Adv Ther; 2008 Aug; 25(8):775-86. PubMed ID: 18670740
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
    Lewis EJ; Hunsicker LG; Clarke WR; Berl T; Pohl MA; Lewis JB; Ritz E; Atkins RC; Rohde R; Raz I;
    N Engl J Med; 2001 Sep; 345(12):851-60. PubMed ID: 11565517
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum levels of the advanced glycation end products Nepsilon-carboxymethyllysine and pentosidine are not influenced by treatment with the angiotensin receptor II type 1 blocker irbesartan in patients with type 2 diabetic nephropathy and hypertension.
    Busch M; Franke S; Wolf G; Rohde RD; Stein G;
    Nephron Clin Pract; 2008; 108(4):c291-7. PubMed ID: 18434751
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiac and renal protective effects of irbesartan via peroxisome proliferator-activated receptorγ-hepatocyte growth factor pathway independent of angiotensin II Type 1a receptor blockade in mouse model of salt-sensitive hypertension.
    Kusunoki H; Taniyama Y; Rakugi H; Morishita R
    J Am Heart Assoc; 2013 Apr; 2(2):e000103. PubMed ID: 23608606
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination therapy of angiotensin II receptor blocker and calcium channel blocker exerts pleiotropic therapeutic effects in addition to blood pressure lowering: amlodipine and candesartan trial in Yokohama (ACTY).
    Maeda A; Tamura K; Kanaoka T; Ohsawa M; Haku S; Azushima K; Dejima T; Wakui H; Yanagi M; Okano Y; Fujikawa T; Toya Y; Mizushima S; Tochikubo O; Umemura S
    Clin Exp Hypertens; 2012; 34(4):249-57. PubMed ID: 22571446
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Beneficial action of candesartan cilexetil plus amlodipine or ACE inhibitors in chronic nondiabetic renal disease.
    Homma K; Hayashi K; Kanda T; Yoshioka K; Takamatsu I; Tatematsu S; Kumagai H; Wakino S; Saruta T
    J Hum Hypertens; 2004 Dec; 18(12):879-84. PubMed ID: 15295613
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acute angiotensin II receptor blockade improves insulin-induced microvascular function in hypertensive individuals.
    Jonk AM; Houben AJ; Schaper NC; de Leeuw PW; Serné EH; Smulders YM; Stehouwer CD
    Microvasc Res; 2011 Jul; 82(1):77-83. PubMed ID: 21514308
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Amlodipine seems to be superior to valsartan in decreasing microalbuminuria in newly diagnosed hypertensive patients: a novel effect to be explained with hyperfiltration?
    Ay SA; Cakar M; Karaman M; Balta S; Demirkol S; Unlu M; Kurt O; Altun B; Akhan M; Arslan E; Koc B; Bulucu F
    Ren Fail; 2013; 35(3):357-60. PubMed ID: 23297711
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: a sequential, randomized, double-blind clinical trial.
    Derosa G; Cicero AF; D'Angelo A; Fogari E; Salvadeo S; Gravina A; Ferrari I; Fassi R; Fogari R
    Clin Ther; 2007 Apr; 29(4):602-10. PubMed ID: 17617283
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Greater efficacy of aldosterone blockade and diuretic reinforcement vs. dual renin-angiotensin blockade for left ventricular mass regression in patients with resistant hypertension.
    Azizi M; Perdrix L; Bobrie G; Frank M; Chatellier G; Ménard J; Plouin PF
    J Hypertens; 2014 Oct; 32(10):2038-44; discussion 2044. PubMed ID: 24983187
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antihypertensive therapy with CCB/ARB combination in older individuals: focus on amlodipine/valsartan combination.
    Kostis JB
    Am J Ther; 2010; 17(2):188-96. PubMed ID: 19433970
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapy with the Combination of Amlodipine and Irbesartan Has Persistent Preventative Effects on Stroke Onset Associated with BDNF Preservation on Cerebral Vessels in Hypertensive Rats.
    Hasegawa Y; Nakagawa T; Uekawa K; Ma M; Lin B; Kusaka H; Katayama T; Sueta D; Toyama K; Koibuchi N; Kim-Mitsuyama S
    Transl Stroke Res; 2016 Feb; 7(1):79-87. PubMed ID: 25533877
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plasma renin activity and aldosterone concentration are not altered by the novel calcium channel antagonist, azelnidipine, in hypertensive patients.
    Kondo T; Goto R; Sonoda K; Yasuda T; Ono K; Takaki Y; Yatsuda R; Miyamura N; Araki E
    Intern Med; 2010; 49(7):637-43. PubMed ID: 20371952
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Irbesartan reduces common carotid artery intima-media thickness in hypertensive patients when compared with atenolol: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) study.
    Mörtsell D; Malmqvist K; Held C; Kahan T
    J Intern Med; 2007 May; 261(5):472-9. PubMed ID: 17444886
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of the T/L-type calcium channel blocker benidipine on albuminuria and plasma aldosterone concentration. A pilot study involving switching from L-type calcium channel blockers to benidipine.
    Tani S; Takahashi A; Nagao K; Hirayama A
    Int Heart J; 2014; 55(6):519-25. PubMed ID: 25310932
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.